<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00810004</url>
  </required_header>
  <id_info>
    <org_study_id>FERGI-MAIN</org_study_id>
    <nct_id>NCT00810004</nct_id>
  </id_info>
  <brief_title>Maintenance Treatment of Iron Deficiency in IBD Patients</brief_title>
  <acronym>FER-IBD-MAIN</acronym>
  <official_title>A Multi-centre, Randomised, Prospective, Single-blinded, Controlled Study to Investigate the Efficacy and Safety of a Standardised Maintenance Dosage Regimen of Intravenous Ferric Carboxymaltose (FERINJECT®) Versus Placebo in Patients With Iron Deficiency Caused by Inflammatory Bowel Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vifor Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Parexel</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vifor Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the treatment of iron deficiency in IBD patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">October 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy of maintenance treatment of iron deficiency</measure>
    <time_frame>8 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">245</enrollment>
  <condition>Iron Deficiency</condition>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Ferinject</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion of iron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>NaCL 0,9%</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferinject</intervention_name>
    <description>Intravenous infusion of iron</description>
    <arm_group_label>Ferinject</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Non-anaemic patients treated in the FERGI-CORRECTION study (Hb ≥12 g/dL female, ≥13 g/dL&#xD;
        male), independent of ferritin value.&#xD;
&#xD;
        Females of child-bearing potential must have a negative urine pregnancy test at screening&#xD;
        and be practising an acceptable method of birth control during the study and for up to 1&#xD;
        month after the last dose of study medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Chronic alcohol abuse (alcohol consumption &gt;20 g/day).&#xD;
&#xD;
        Presence of portal hypertension with oesophageal varices. History of erythropoietin,&#xD;
        intravenous or oral iron therapy, or blood transfusion in 12 weeks prior to screening.&#xD;
&#xD;
        Known hypersensitivity to FERINJECT®.&#xD;
&#xD;
        History of acquired iron overload.&#xD;
&#xD;
        Myelodysplastic syndrome.&#xD;
&#xD;
        Pregnancy or lactation.&#xD;
&#xD;
        Known active infection, clinically significant overt bleeding, active malignancy. Known&#xD;
        chronic renal failure.&#xD;
&#xD;
        Surgery with relevant blood loss (defined as Hb drop &lt;2 g/dL) in the 3 months prior to&#xD;
        screening or planned surgery within the following 3 months.&#xD;
&#xD;
        Chronic liver disease or increase of liver enzymes (alanine aminotransferase ([ALT],&#xD;
        aspartate aminotransferase [AST]) &gt;3 times the upper limit of normal range.&#xD;
&#xD;
        Known human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome (AIDS),&#xD;
        hepatitis B virus (HBV) or hepatitis C virus (HCV) infection.&#xD;
&#xD;
        Inability to fully comprehend and/or perform study procedures in the investigator's&#xD;
        opinion.&#xD;
&#xD;
        Participation in any other interventional study (except correction study) within 1 month&#xD;
        prior to screening.&#xD;
&#xD;
        Body weight &lt;35 kg.&#xD;
&#xD;
        Significant cardiovascular disease, including myocardial infarction within 12 months prior&#xD;
        to study inclusion, congestive heart failure NYHA (New York Heart Association) grade III or&#xD;
        IV, or poorly controlled hypertension according to the judgment of the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph Gasche, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State Scientific Center of Coloproctology of RosMedTekhnolgy</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>December 16, 2008</study_first_submitted>
  <study_first_submitted_qc>December 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2008</study_first_posted>
  <last_update_submitted>December 19, 2012</last_update_submitted>
  <last_update_submitted_qc>December 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

